MG53 suppresses IRF7 to reprogram macrophages and promote antitumor immunity in pancreatic ductal adenocarcinoma
Cell Reports · 2026-10 · 45 (10) · 118000
DOI: 10.1016/j.celrep.2026.118000 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2026-10. Verfasst von Yumeng Pei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China; Zh…. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Interferon Regulatory Factor-7, Macrophages, Pancreatic Neoplasms. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Province Natural Science Foundation, China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
In pancreatic ductal adenocarcinoma (PDAC), the desmoplastic stroma and immunosuppressive tumor microenvironment (TME) present barriers to immunotherapy. Here, we show that MG53 (TRIM72) is a critical regulator of macrophage fate and anti-tumor immunity; its myeloid-specific depletion accelerates PDAC progression by locking macrophages into a suppressive state, whereas its restoration dismantles the immunosuppressive TME. Mechanistically, MG53 binds the Irf7 locus to suppress the pro-tumorigenic myeloid program, and concomitant IRF7 deletion reverses the phenotype of MG53-deficient models. Clinically, an MG53-low/IRF7-high TAM signature correlates with reduced survival across gastrointestinal malignancies, particularly within PDAC cohorts. Using a macrophage-tropic mRNA-LNP platform to restore MG53 expression in vivo, thereby suppressing tumor growth and enhancing antitumor immune activity in PDAC. Our findings demonstrate that MG53 functions as a myeloid checkpoint regulator and suggest mRNA-based reprogramming as a potential strategy to address therapeutic resistance in PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China; Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affi…
- State Key Laboratory of Membrane Biology, Institute of Molecular Medicine, College of Future Technology, Peking University, Beijing 100871, China; Peking-Tsinghua Center for Life Sciences, Beijing 100871, China.
Förderung
- Zhejiang Province Natural Science Foundation
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Pei, Y., Fang, M., Zhang, F., Zhao, D., Li, Y., Huang, J., Liang, X., Xiao, R. P., Liang, T., & Wu, H. K. (2026). MG53 suppresses IRF7 to reprogram macrophages and promote antitumor immunity in pancreatic ductal adenocarcinoma. Cell Reports, 45(10), 118000. https://doi.org/10.1016/j.celrep.2026.118000
Vancouver
Pei Y, Fang M, Zhang F, Zhao D, Li Y, Huang J, et al. MG53 suppresses IRF7 to reprogram macrophages and promote antitumor immunity in pancreatic ductal adenocarcinoma. Cell Reports. 2026;45(10):118000. doi:10.1016/j.celrep.2026.118000
BibTeX
@article{Pei2026,
author = {Pei, Yumeng and Fang, Meng and Zhang, Fan and Zhao, Danyang and Li, Yini and Huang, Jinyan and Liang, Xingmei and Xiao, Rui-Ping and Liang, Tingbo and Wu, Hong-Kun},
title = {MG53 suppresses IRF7 to reprogram macrophages and promote antitumor immunity in pancreatic ductal adenocarcinoma},
journal = {Cell Reports},
year = {2026},
volume = {45},
number = {10},
pages = {118000},
doi = {10.1016/j.celrep.2026.118000}
}
EUVIMED